Enanta Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jay R. Luly
- Full Time Employees
- 120
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4 Kingsbury Avenue Watertown MA United States of America 02472
- IPO Date
- Mar 21, 2013
- CIK
- 0001177648
- Website
- enanta.com
- Similar Companies
- Business
- Enanta Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, specializing in the discovery and advancement of small molecule therapeutics for challenging viral infections and various immunological conditions. The firm’s active research and development pipeline includes programs aimed at respiratory syncytial virus (RSV), hepatitis B virus (HBV), and emerging immunology targets such as KIT and STAT6 inhibition for inflammatory diseases. Notably, Enanta continues to benefit from its collaboration with AbbVie, having contributed glecaprevir to the highly successful MAVYRET® regimen for chronic hepatitis C virus infection. Established in 1995, Enanta Pharmaceuticals, Inc. has its headquarters in Watertown, Massachusetts.
Company News
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average – Should You Sell?
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)